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Aluminum loading in children with chronic renal failure. Plasma alu-
minum levels were measured in 17 children with chronic renal failure
who were receiving aluminum containing antacids for the control of
hyperphosphatemia. Seven children were on hemodialysis, five on
peritoneal dialysis, and five were awaiting dialysis with creatinine
clearances between 10 to 20 cc/min/l.73 m2. Plasma aluminum levels
correlated directly with oral aluminum dosage; extremely high levels
were documented in small, nondialyzed children. Bone aluminum lev-
els were measured in four children with high plasma levels and con-
firmed significant aluminum loading. Other factors such as the level of
aluminum in dialysate and tap water were measured and were not con-
tributory. All patients with plasma aluminum levels greater than 100
.tg/liter had signs of aluminum toxicity and were receiving greater than
75 mg/kg/day of elemental aluminum orally. We concluded that chil-
dren who require greater than 30 mg/kg/day of elemental aluminum to
control hyperphosphatemia should have plasma aluminum levels mon-
itored and/or be considered for other forms of therapy including more
restricted diets and earlier or more aggressive dialysis.
Surcharge aluminique chez des enfants en insuffisance rénale chron-
ique. Les concentrations plasmatiques d'aluminium ont été détermi-
nées chez 17 enfants en insuffisance rénale chronique recevant des an-
tiacides contenant de l'aluminium pour controler leur hyperphospha-
témie. Sept enfants étaient en hémodialyse, cinq en dialyse përitonéale
et cinq étaient en attente de dialyse avec des clearances de Ia créatinine
entre 10 a 20 cc/min/l.73 m2. Les niveaux plasmatiques d'aluminium
étaient directement corrélés a Ia dose orale d'aluminium; des niveaux
extrémement elevés ont été documentés chez de petits enfants non
dialyses. Les niveaux d'aluminium osseux ont ëtë mesurés chez qua-
tre enfants avec des niveaux plasmatiques élevés et confirmant une sur-
charge aluminique significative. D'autres facteurs comme le niveau
d'aluminium dans le dialysat et l'eau du robinet ont ëté mesurés mais
n'étaient pas contributifs. Tous les malades dont l'aluminium plasma-
tique dépassait 100 g/1itre avaient des signes de toxicité aluminique
et recevaient >75 mg/kg/jour d'aluminium-élëment oralement. Nous
avons conclu que les enfants nécessitant >30 mg/kg/jour d'aluminium-
élëment pour contrôler leur hyperphosphatCmie devraient avoir leur
niveau plasmatique d'aluminium surveillé, et/ou devraient ëtre cand-
idats a d'autres formes de traitement notamment des regimes plus re-
streints et une dialyse plus précoce ou plus agressive.
Epidemiologic and animal data have implicated aluminum as
one causative factor for dialysis dementia and osteomalacic os-
teodystrophy [1—4]. Previous work has demonstrated a high
correlation between aluminum loading and the dialysate alu-
minum in hemodialysis patients [3]. There is less definite cor-
relation with oral intake of aluminum, although there are sub-
stantial data to indicate that oral loading can take place [5].
Previous reports have suggested aluminum toxicity in chil-
dren, but increased plasma and tissue levels have only re-
cently been documented [6—8].
The extremely high rate of developmental delay and bone
disease in medically managed children with chronic renal fail-
ure [91 has prompted us to explore further the issue of alumi-
num toxicity in childhood secondary to oral exposure.
Methods
Blood samples were collected by venipuncture. Red cells
and plasma were separated by centrifuge immediately after col-
lection, and plasma was placed in plastic test tubes to avoid
contamination. Samples were then frozen until the day the
analysis was performed. Plasma levels were determined in du-
plicate by methods previously described using a flameless
atomic absorption spectrophotometer (model 305B, Perkin
Elmer, Norwalk, Connecticut) [51. Bone biopsy was per-
formed with a Jamshedi needle sampling of the iliac crest. Bone
aluminum was measured by flameless atomic absorption using
methods previously described [10].
The patients in our study were 0.5 to 18 years of age, either
enrolled in our dialysis program or followed in our renal clinic,
with the exception of patients 16 and 17 whose samples were
sent to our laboratory from other centers after the children de-
veloped bone disease and encephalopathy. All children had re-
ceived aluminum-containing phosphate binders as Al(OH)3 or
A12(C03)3 to control serum phosphorus between 4.5 to 6.5
mg/dl. Two children in our program with high plasma levels of
aluminum subsequently had bone biopsies and then an analy-
sis of aluminum was made from their peritoneal dialysate. Alu-
minum clearance was measured in four other children in the
peritoneal dialysis group, but dialysate levels were so low that
they were felt to be unreliable. Aluminum clearance by he-
modialysis has been previously described [11, 12] and was not
measured in this population.
Results
Plasma aluminum, bone aluminum, patient age and weight,
average aluminum dose in milligrams per kilogram, and dura-
tion of aluminum therapy are reported in Table 1. It should be
noted that patient 13 is reported when he was nondialyzed and
then at two different stages of dialysis when his dose of phos-
phate binders was changed. Duration of therapy for children on
dialysis was calculated only during the time the children were
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Plasma Bone
Pa- levela leveib Dose Duration
tient fig! mgi Age Weight mg/kg! therapy
no. liter kg years kg day months
Hemodi- 1 26 — 18 41 20 33
alysis 2
3
4
5
6
7
48
13
10
72
26
42
—
—
—
—
—
—
13
15
10
10
18
14
18
60
23
20
42
25
48
58
45
52
13
84
44
7
3
6
34
60
Perito- 8 62 — 6 14 39 9
neal 9
10
11
12
13
29
58
68
133
177
—
—
—
82
—
10
11
11
3.5
1.6
23
21
20
8.6
9
47
82
29
210
93
6
12
36
15
21
No dial- 14 65 — 0.5 6 34 5
ysis 13c
13c
15
16d
17a
363
312
98
334
124
85
—
—
156
226
1.1
1.3
12
3
3
7.6
8
30
—
133
105
29
108
15
17
30
25
7
a The plasma level in normal subjects is less than 10 jig/liters (5).
b The bone level in normal subjects is less than 3.3 mg/kg (14).
These values represent the same child at various stages of therapy.
Analysis on this child was done at the University of Colorado
Health Sciences Center laboratory; the child was from another institu-
tion [81.
Analysis on this child was done at the University of Colorado
Health Sciences Center laboratory; the child was from another institu-
tion (unreported).
Normal
actually dialyzed; records were too incomplete to assess their
pre-dialysis therapy. Actual duration of therapy is reported in
five nondialyzed children.
All children who received aluminum-containing phosphate
binders exhibited higher than normal (N = <10 jig/liter) se-
rum aluminum levels (Fig. 1, 2 P < 0.005), The mean level in
the hemodialysis group (HD) was 33.9 21.8 jig/liter, in the
Plasma Al
pg/liter
42.4 25 33.9 21.8
81.4 79.6 87 55.5
77.3 50 216 134
Abbreviations: HD, hemodialysis; PD, peritoneal hemodialysis; ND,
non-dialyzed.
peritoneal group (PD) 87.8 55 jig/liter, and in the nondi-
alyzed (ND) group 216 134 jig/liter (mean 1 SD).
Patients 12, 13, 16, and 17 were all children diagnosed with
renal failure as infants; phosphate binders were used early in
their treatment. They exhibited extremely high Al levels com-
pared to normal subjects (Table 1). In fact, several had the
highest serum levels ever reported in individuals who had been
exposed to oral rather than parenteral aluminum. As shown in
Table 2, the average age of nondialyzed patients was younger
than those on I-ID or PD. Four children displayed a clinical
syndrome suggestive of aluminum toxicity. Patient 12 had se-
vere growth failure, osteopenia with fractures, and mild devel-
opmental delay. Patient 13 had growth failure, osteopenia with
an intermittent failure to walk and, although considered to be
grossly neurologically normal, was delayed developmentally
compared to a non-identical, same-sex twin. Patient 16 (pre-
viously reported by Griswold [8]) had growth delay, os-
teomalacia, and severe encephalopathy including myoclonic
seizures with a loss of speech. Patient 17 was a child from an-
other institution with prune-belly syndrome who was never dia-
lyzed. At 2 years of age he had a clearance of 15 ml/min/1.73
m2 with severe failure to thrive, anemia, and rickets. At that
time he was started on aluminum-containing phosphate bind-
ers. At 3 years of age he developed seizures refractory to
therapy, and aluminum levels were documented by our labo-
ratory to be high (reported in Table 1) in both plasma and bone.
The child was subsequently institutionalized without change in
therapy. He died at age 6 with evidence of severe encephalopa-
thy and osteomalacia and high tissue and plasma aluminum lev-
els measured by another laboratory.
The direct correlation between elemental aluminum dose and
plasma aluminum levels (r = 0.600, P < 0.01) is expressed in
Figure 2.
Patients 12 and 13 had dialysate Al measured after being on
chronic ambulatory peritoneal dialysis for at least 6 weeks.
With a plasma level of 133 jig/liter, patient 12's dialysate level
was 42 jig/liter; patient 13 had plasma of 177 jig/liter with a di-
alysate level of 45 jig/liter. The aluminum level on infused di-
alysate was 2 jig/liter.
Discussion
Aluminum is widespread in nature making up approximately
8% of the earth's crust. Lungs, skin, and gastrointestinal tract
basically exclude the largest amount of environmental alumi-
num [13], and the small amounts that are absorbed are ex-
creted in individuals with normal glomerular filtration rate
(GFR). Patients with renal failure, however, have been shown
previously to accumulate large amounts of aluminum in tissues
including spleen, liver, brain, and bone [3]. Good epidemio-
logic correlation has demonstrated that this abnormal accumu-
Table 1. Patient data Table 2. Summary of patient data
Patient Al dose
group N Age mg/kg/day
HD 7 14 ±3.3
ND 5 5.5±6.0
300
200
100
a
E
E
Cu
E
C,,
Cu
HD PD ND
Fig. 1. Plasma aluminum levels expressed as the mean 1 SD in he-
modialysis patients (HD), peritoneal dialysis patients (PD), and pa-
tients in chronic renal .failure not on dialysis (ND).
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Fig. 2. Elemental aluminum dose versus plasma aluminum of patients
including those on hemodialysis, peritoneal dialysis, and not on
dialysis.
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consisting of heteropolyuronic acid have recently been clini-
cally tested in Europe and appear to be safe and efficacious on
a limited basis [151. They are not yet available in the United
States. Earlier dialysis may be helpful especially with low mag-
nesium-containing dialysate to allow use of magnesium-con-
taining phosphate binders [16]. Peritoneal clearance of alumi-
num without chelation in our patients is moderate, reflecting
that aluminum is highly tissue- and protein-bound. Further
studies are needed to define the nature of the protein binding.
Our study suggests that the very high levels of aluminum
seen in nondialyzed children are directly related to the large
amounts of binder required to control serum phosphorus. All
patients with plasma aluminum levels greater than 100 gig/liter
r= 0.600 were receiving greater than 75 mg/kg/day of elemental alumi-
num and showed signs of toxicity. In comparison to adults who
usually consume less than 30 mg/kg/day, this represents an ex-
tremely large dose of aluminum and probably accounts for the
toxicity noted in small children. In view of this, it seems rea-
sonable to recommend that if children require more than 30
mg/kg/day of elemental aluminum, they have aluminum levels
monitored to document that plasma levels are not reaching a
range associated with toxicity and/or that they be considered
for other methods of management of hyperphosphatemia apart
from aluminum-containing phosphate binders.
lation causes encephalopathy and vitamin D-resistant os-
teomalacia [1—4]. The highest levels of tissue accumulation
occurred when patients were directly exposed to dialysate con-
taminated with aluminum. In fact, a severe form of dialysis en-
cephalopathy leading to rapid demise has virtually disappeared
from dialysis units where aluminum levels in dialysate have
been strictly controlled [14]. The relationship of oral aluminum
intake and tissue loading and toxicity has not been as clearly
defined, and there is little evidence that oral loading causes
very high levels of plasma and tissue aluminum in adults with
the frequency that is seen in the children we studied, Studies
in children documenting aluminum levels correlated with the
dose of oral intake have also been limited, although isolated re-
ports have noted children with encephalopathic symptoms
seemingly related to high oral aluminum intake [6, 71.
Our study shows a direct correlation between oral elemental
aluminum dose and plasma levels. However, since aluminum
is highly tissue-bound, plasma aluminum levels cannot be as-
sumed to directly reflect the amount of tissue loading. High
plasma levels are compatible with high bone levels, but indi-
viduals with similar plasma levels can have markedly different
bone levels (see patients 12 and 17, 16 and 13, Table I). Tissue
levels are most likely related to multiple factors including the
level of GFR, duration of therapy, total dose of aluminum, and
tissue turnover rate.
The patients who appear to be at most risk for aluminum tox-
icity are children on maximum binder therapy to control se-
rum phosphorus before dialysis is begun, suggesting that man-
agement should include more aggressive limitation of phos-
phate intake with low phosphorus formula and/or essential
amino acid supplements so that aluminum-containing phos-
phate binders are not as necessary to prevent hyperphospha-
temia. We now use oral calcium carbonate as our initial phos-
phate binder and only utilize aluminum when calcium carbon-
ate is not tolerated either secondary to hypercalcemia or
prohibitive volume of antacid. Alternative phosphate binders
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